0001213900-26-036946
SEC filingFY2025 saw Cadrenal Therapeutics post wider operating and net losses alongside increased cash burn, with near-term capital needed to fund planned operations.
As outlined in Item 1A Risk Factors, Cadrenal expects to incur significantly higher operating and capital expenditures in the foreseeable future, with no guarantee of achieving revenue or profitability in the near term. The company will need to secure significant additional capital to fund planned clinical trials, commercialization efforts, expanded research and development activities, and ongoing costs associated with operating as a public company. The broader pharmaceutical industry also faces persistent pricing pressures due to the growing influence of managed care organizations and ongoing legislative proposals that may impact product economics if the company’s pipeline candidates are successfully developed and approved. Management is evaluating a range of funding options to support its operating plan, including strategic partnerships, public or private equity offerings, and debt financing arrangements.